Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,902B 2.06B 1.78B 1.66B 1.53B 2.87B 196B 2.92B 19.52B 7.66B 98.23B 7.73B 7.56B 325B P/E 2026 *
-89x
P/E 2027 * -91.6x
Enterprise Value 2,902B 2.06B 1.78B 1.66B 1.53B 2.87B 196B 2.92B 19.52B 7.66B 98.23B 7.73B 7.56B 325B EV / Sales 2026 *
363x
EV / Sales 2027 * 264x
Free-Float
83.34%
Yield 2026 *
-
Yield 2027 * -
07-30 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-28 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-31 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-07 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
27/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/08/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+13.70%
1 week+45.36%
Current month+45.36%
1 month+13.51%
3 months-17.98%
6 months+2.84%
Current year-1.85%
1 week 103,700
Extreme 103700
139,700
1 month 86,600
Extreme 86600
141,800
Current year 86,600
Extreme 86600
217,000
1 year 48,850
Extreme 48850
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 31/01/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 27/03/2022
Director TitleAgeSince
Director/Board Member 61 18/03/2019
Director/Board Member 55 18/03/2019
Chairman 54 31/01/2010
Date Insider Type Main position Quantity % Market Cap.
28/02/25 Fiscal year

Chief Technology Officer

8,000 0.0433%
28/02/25 Fiscal year

Director

30,000 0.1625%
Change 5-day change 1-year change 3-year change Capi.($)
+13.70%+45.36%+164.49%+761.25% 1.81B
+8.49%+20.55%+70.77%+103.07% 68.12B
+0.45%+6.12%+38.54%+67.70% 55.18B
+1.36%+34.80%+17.56%+484.11% 28.63B
+0.57%+19.05%+57.08%+5.18% 23.99B
+0.28%+1.64%-14.18%-11.09% 23.53B
-0.49%+7.58%+46.30%-22.84% 18.45B
-2.04%+9.24%+31.14%+650.71% 16.44B
+7.26%+25.47%+221.03%+383.67% 15.83B
-1.14%-3.38%+42.21%+151.54% 13.4B
Average +2.82%+12.32%+67.49%+257.33% 26.54B
Weighted average by Cap. +2.78%+13.29%+53.56%+166.70%

Financials

2026 *2027 *
Net sales 8B 5.68M 4.91M 4.58M 4.21M 7.91M 540M 8.04M 53.79M 21.11M 271M 21.31M 20.85M 895M 11B 7.8M 6.75M 6.3M 5.78M 10.88M 743M 11.05M 73.97M 29.03M 372M 29.31M 28.67M 1.23B
Net income -31B -21.99M -19.03M -17.77M -16.3M -30.65M -2.09B -31.14M -208M -81.81M -1.05B -82.59M -80.79M -3.47B -30B -21.28M -18.41M -17.19M -15.77M -29.67M -2.03B -30.14M -202M -79.18M -1.02B -79.93M -78.18M -3.36B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
09/08/26 137,800.00 +13.70% 403,251
07/08/26 ₩121,200.00 -1.86% 151,282
06/08/26 ₩123,500.00 +1.65% 184,316
05/08/26 ₩121,500.00 +1.42% 227,478
04/08/26 ₩119,800.00 +13.66% 484,026
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock